Alzheimer: Researchers find two cancer drugs reverse damaged gene behaviour in mice
gene behaviour
in
Alzheimer's disease
with that caused by 1,300 drugs approved for use in the US has found that a combination of two
cancer drugs
could slow the neurodegenerative disease in mice, indicating a promise in reversing symptoms in humans.
Alzheimer's disease is an ageing-related disorder in which cognitive function steadily declines, affecting speech and memory, and eventually can interfere with everyday activities.
Scientists at the University of California, San Francisco, and Gladstone Institutes in the US first saw how gene behaviour was affected in Alzheimer's disease in a single brain cell.
The researchers then looked at 1,300 drugs approved by the US Food and Drug Administration (FDA) and which of them reversed the damage.
The next stage of the study, published in the journal 'Cell', analysed electronic medical records of about 1.4 million patients and found that patients who took some of these drugs for treating conditions other than Alzheimer's disease were less likely to get the ageing-related neurological disorder.
Testing the top two drug candidates -- '
letrozole
' and '
irinotecan
', both of which are cancer medications -- in a mouse model having Alzheimer's disease, the researchers found that brain degeneration was reduced and a restored ability to remember.
Letrozole is usually prescribed for treating breast cancer, and irinotecan for colon and lung cancer.
The combined effects of two drugs were found to reverse damaged gene behaviour in neurons and glia (a type of brain cells that surround and support neurons).
Further, toxic clumps of proteins and brain degeneration -- hallmark features of Alzheimer's -- were found to be reduced and memory restored, the researchers said.
The team added that out of 1,300 drugs, 86 reversed gene behaviour changes in one type of brain cell and 25 reversed them in other types. However, only 10 had been approved for use in humans by the FDA.
"Thanks to all these existing data sources, we went from 1,300 drugs, to 86, to 10, to just five," said lead author Yaqiao Li, a postdoctoral scholar at Gladstone Institutes.
"Alzheimer's disease comes with complex changes to the brain which has made it tough to study and treat, but our computational tools opened up the possibility of tackling the complexity directly," said co-senior author Marina Sirota, professor of paediatrics and an interim director at the University of California.
Co-senior author Yadong Huang, director of the center for translational advancement at Gladstone Institutes, said, "Alzheimer's is likely the result of numerous alterations in many genes and proteins that, together, disrupt brain health."
"This makes it very challenging for drug development -- which traditionally produces one drug for a single gene or protein that drives disease," Huang said.
The electronic medical records analysed in the study came from the University of California's Health Data Warehouse, which includes anonymised health information on 1.4 million people over the age of 65.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Scroll.in
an hour ago
- Scroll.in
TPSC FSO notification 2025 released; apply from August 7
Tripura Public Service Commission (TPSC) invited online applications from eligible candidates for the recruitment to Food Safety Officer, Group-B Gazetted under Health & Family Welfare Department Govt. of Tripura under Advt. No. 23/2025. Candidates can apply for the posts at from August 7 to September 2, 2025. The recruitment drive aims to fill 16 vacancies. A bachelor's or master's or doctorate degree in Food Technology or Dairy Technology or Biotechnology or Oil Technology or Agriculture Science or Veterinary Sciences or Bio-Chemistry or Microbiology or Chemistry or Medicine from a recognized university is required. More details in the notification: Here's the official notification. Application Fee A fee of Rs 350 applies to General category candidates and Rs 250 is applicable to ST/ SC/ BPL card holders/ Physically Handicapped candidates. Selection Process The applicants will be shortlisted on the basis of the written examination of 85 marks (MCQ type) and the interview/ personality test of 15 (Fifteen) marks.
Time of India
8 hours ago
- Time of India
Air pollution exposure linked to higher dementia risk, major study finds
Long-term exposure to air pollution may significantly raise the risk of developing dementia, according to a major new study involving nearly 29 million people. Published in The Lancet Planetary Health, the research was led by scientists at the University of Cambridge's MRC Epidemiology Unit. It reviewed 51 studies from across North America, Europe, Asia, and Australia to better understand the relationship between air pollutants and cognitive decline. Explore courses from Top Institutes in Please select course: Select a Course Category Digital Marketing MBA others Public Policy Data Science Artificial Intelligence Design Thinking Healthcare PGDM Management Operations Management Cybersecurity Others Data Science Degree Leadership Data Analytics healthcare Finance CXO Project Management MCA Technology Product Management Skills you'll gain: Digital Marketing Strategies Customer Journey Mapping Paid Advertising Campaign Management Emerging Technologies in Digital Marketing Duration: 12 Weeks Indian School of Business Digital Marketing and Analytics Starts on May 14, 2024 Get Details Skills you'll gain: Digital Marketing Strategy Search Engine Optimization (SEO) & Content Marketing Social Media Marketing & Advertising Data Analytics & Measurement Duration: 24 Weeks Indian School of Business Professional Certificate Programme in Digital Marketing Starts on Jun 26, 2024 Get Details The study found strong evidence linking three common pollutants, PM2.5, nitrogen dioxide (NO₂), and soot (black carbon), with an increased risk of dementia, including Alzheimer's disease and vascular dementia. Key findings For every 10 micrograms per cubic metre (μg/m³) increase in PM2.5, the risk of developing dementia rose by 17 percent. A 10 μg/m³ increase in NO₂ was linked to a 3 percent rise in dementia risk. Each 1 μg/m³ increase in soot was associated with a 13 percent higher risk. PM2.5 refers to fine particulate matter less than 2.5 microns in diameter, small enough to enter deep into the lungs and potentially the brain. These particles come from sources such as vehicle exhaust, industrial processes, power plants, wood burning, and construction dust. Live Events Average roadside PM2.5 levels in Central London in 2023 were around 10 μg/m³, while NO₂ levels were approximately 33 μg/m³. Possible biological mechanisms Researchers believe air pollution may contribute to dementia through oxidative stress and inflammation, processes that damage brain cells and are known to play a role in the development of neurodegenerative conditions. Some pollutants may reach the brain directly via the bloodstream or through the olfactory nerve, while others may cause indirect effects through the cardiovascular and respiratory systems. Unequal exposure The majority of participants in the analysed studies were white and from high-income countries. However, the researchers noted that marginalised and low-income communities, who are more likely to be exposed to air pollution, are underrepresented in research. 'Efforts to reduce exposure to these key pollutants are likely to help reduce the burden of dementia on society,' said co-author Clare Rogowski. Public health implications Globally, over 57 million people are estimated to be living with dementia. That number is projected to rise to 152.8 million by 2050, according to the World Health Organization. While other factors such as age, genetics, diet, and lifestyle play significant roles in dementia risk, researchers argue that environmental policies should be considered part of dementia prevention strategies. The study was funded by the European Research Council and the European Union's Horizon Europe Framework Programme.
Time of India
14 hours ago
- Time of India
US lawmakers press FDA to target knockoff weight-loss drugs
Dozens of lawmakers are urging US health regulators to crack down on the booming market for knockoff weight-loss drugs amid mounting concerns over their potential safety risks. On Friday, a group of more than 80 bipartisan lawmakers asked the US Food and Drug Administration to stop counterfeit and copycat versions of GLP-1 drugs like Wegovy and Zepbound from flooding the market-a problem that emerged over the last year. Explore courses from Top Institutes in Please select course: Select a Course Category Cybersecurity MCA Data Science Degree Leadership PGDM Public Policy Operations Management others Others Product Management healthcare Digital Marketing MBA Technology Project Management CXO Finance Artificial Intelligence Healthcare Data Analytics Management Design Thinking Data Science Skills you'll gain: Duration: 10 Months MIT xPRO CERT-MIT xPRO PGC in Cybersecurity Starts on undefined Get Details "We are concerned about recent reports revealing a surge in illegal and counterfeit anti-obesity medications," they wrote in a letter to FDA commissioner Marty Makary. "Undoubtedly, illegal counterfeit medications pose an increased risk to patient safety with sometimes fatal consequences." by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Play War Thunder now for free War Thunder Play Now Undo The group-spearheaded by Representatives Richard Hudson of North Carolina and Herb Conaway of New Jersey-asked the agency to ramp up enforcement over illegally imported weight-loss drugs. They suggested issuing warning letters and better monitoring non-compliant online retailers and so-called compounding pharmacies that sell the medicines. The lawmakers also said the FDA should work in tandem with US Customs and Border Patrol agents to stop Chinese entities from shipping unsafe weight-loss drugs into the US. They requested an update on the FDA's efforts by July 30, given the "urgency" of the situation. Live Events A spokesperson for the FDA said the agency will work with the US Department of Health and Human Services to provide a "complete and thorough" response to the issues raised in the lawmakers' letter. "Any effort to undermine America's supply of safe medicines is an issue that FDA takes seriously," the spokesperson said. "And we are deeply committed to strengthening the oversight of imported products at US ports of entry." In recent years, the popularity of GLP-1 drugs has led to an explosion of copycats and counterfeits made by companies seeking to capitalise on the hype. State-licensed pharmacies were temporarily allowed to make copies of the drugs during a supply shortage but are no longer permitted to do so after Novo Nordisk and Eli Lilly boosted production. Still, some pharmacies have refused to wind down their operations while others have pivoted to selling the drugs in lower doses in order to avoid regulatory scrutiny. Counterfeit drugs are made by unregistered entities typically using illegally imported ingredients. As recently as April, there continue to be instances when counterfeit Ozempic pens covertly enter the drug supply chain undetected. Some patients are also purchasing ingredients directly from online sellers in an attempt to make the drugs themselves at home. In both cases, the medications don't go through the same rigorous approval process as brand-name drugs made by Novo and Lilly. Experts worry the lack of oversight is putting patients at risk. The FDA has said it's aware of hospitalisations potentially linked to the copycat drugs, but that adverse events are likely being underreported. "We support the bi-partisan call for the FDA to crack down on counterfeit and illegally sold weight-loss drugs," said a spokesperson for Hims & Hers Health, one of the telehealth firms that sells compounded GLP-1s. "We appreciate lawmakers' recognition that legitimate compounded medications dispensed by state-regulated pharmacies are not counterfeit. Patient safety must always come first." Novo and Lilly have discouraged consumers from using compounded and counterfeit products, including suing telehealth firms that sell the copycat versions and working with border agents to seize illegal shipments.
